Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:12 PM ET 8-K
M&A Deal Surgery Partners, Inc. SGRY

Surgery Partners Signs $6B M&A Deal with HealthSpan Partners

Surgery Partners announced an amendment to its merger agreement with HealthSpan Partners, increasing the cash consideration to $25.00 per share following an unsolicited competing proposal. The deal represents an enterprise value of approximately $6.0 billion and includes a 'Ticking Fee' if the merger does not close by March 1, 2027.

Value
$6B
Counterparty
HealthSpan Partners

“Our financial results in the third quarter reflect the impact of the successful Idaho Falls divestiture and sustained momentum in our core business, underscoring the value of our short-stay surgical platform. Additionally, the recently announced amended merger agreement with HealthSpan Partners serves as further validation of our unique offering, while representing a compelling outcome for our patients, physicians, stockholders, and other stakeholders.”

Eric Evans, Chief Executive Officer
4:12 PM ET 8-K
Financial Results Structure Therapeutics Inc. GPCR

Structure Therapeutics Financial Results

Structure Therapeutics reported third quarter 2026 financial results and provided a corporate update on its oral small molecule obesity portfolio, including the enrollment of its Phase 3 ACCOMPLISH program for aleniglipron. The company ended the quarter with $1.2 billion in cash and investments, which is expected to fund operations through 2028. Topline data from the registrational Phase 3 trials are anticipated in the second half of 2028.

“With our Phase 3 ACCOMPLISH program underway, we are advancing aleniglipron toward potential registration while building a broader portfolio of differentiated oral small molecule treatments for chronic weight management.”

Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics

“We are also advancing our oral small molecule amylin portfolio by progressing the multiple ascending dose clinical trial of ACCG-2671, preparing to initiate a Phase 1 clinical trial of ACCG-3535 and exploring GLP-1 combination approaches.”

Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics
4:12 PM ET 10-Q
Financial Results Zentalis Pharmaceuticals, Inc. ZNTL

Zentalis Pharmaceuticals Q3 2026 Results: Net Loss of $28.8M, Loss Widens

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, azenosertib (ZN-c3), for various oncology indications including ovarian cancer. As of November 4, 2026, the company had 98,265,863 shares of common stock outstanding and is prioritizing its Phase 3 ASPENOVA and Phase 2 DENALI trials.

Key figure
Net loss $28.8M
4:12 PM ET 8-K
Financial Results H&R Block Inc HRB

H&R Block Financial Results

H&R Block reported fiscal 2027 first quarter results with revenue increasing 10% to $224.3 million, driven by growth in international and small business services. The company reaffirmed its full-year fiscal 2027 outlook and returned capital to shareholders through $100 million in share repurchases and a quarterly dividend declaration of $0.46 per share.

“We are pleased with our start to fiscal 2027, including revenue growth of more than 10%. At the same time, we continue advancing strategic initiatives designed to enhance the client experience and support future growth. Our focus remains on executing our strategy and positioning H&R Block for long-term success.”

Curtis Campbell, president and chief executive officer

“Our financial position remains strong, and we continue to execute our disciplined capital allocation priorities. During the first quarter, we invested in the business to support future growth while returning capital to shareholders through dividends and share repurchases. We remain confident in the assumptions underlying our fiscal 2027 outlook and are reaffirming our guidance.”

Tiffany Mason, chief financial officer
4:12 PM ET Form 4
Insider Selling Capital One Financial Corp COF

Capital One Financial Insider Peter E. Raskind Sells $339K of Stock

Peter E. Raskind sold 1,681 shares of Capital One Financial Corp at $201.79 a share, worth $339K in total on Nov 6, 2026. Shares held after the trade: 32,715 (-4.9%).

Value
$339K
Shares
1,681
Price
$201.79
Holding change
-4.9%
Trade date
Nov 6, 2026
4:12 PM ET 10-Q
Financial Results Ceva Inc CEVA

Ceva Q3 2026 Results: Net Loss of $2.3M, Loss Narrows

CEVA INC reported total revenues of $85.1 million for the nine months ended September 30, 2026, a 9% increase compared to the same period in 2025. Despite the revenue growth, the company recorded a net loss of $9.7 million for the period, driven by higher operating expenses in research and development and general and administrative functions.

Key figure
Net loss $2.3M
4:12 PM ET 8-K
Financial Results Hims & Hers Health, Inc. HIMS

Hims & Hers Health Financial Results

Hims & Hers Health reported Q3 2026 revenue of $890.4 million, a 49% year-over-year increase driven by significant international growth and a 13% rise in subscribers to 2.8 million. The company reported a net loss of $33.0 million compared to a profit in the prior year, while tightening its full-year revenue guidance and reducing its Adjusted EBITDA outlook.

Term
Q3 2026

“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.”

Andrew Dudum, co-founder and CEO

“In the third quarter, we continued to apply what we’ve learned to make deliberate strategic decisions to position Hims & Hers for durable, multi-year growth.”

Yemi Okupe, Chief Financial Officer
4:12 PM ET 10-Q
Financial Results Life360, Inc. LIF

Life360 Q3 2026 Results: Net Income $22.5M, Up 129.7% YoY

Life360 reported total revenue of $174.1 million for the quarter ended September 30, 2026, representing significant growth from $124.5 million in the prior year period, driven largely by subscription and advertising revenue. The company maintained a strong balance sheet with $333.1 million in cash and cash equivalents and showed a reduction in its accumulated deficit to $108.5 million.

Key figure
Net income $22.5M · +129.7% YoY
4:12 PM ET 8-K
Financial Results Clearway Energy, Inc. CWEN

Clearway Energy Financial Results

Clearway Energy reported Q3 2026 net income of $123 million and Adjusted EBITDA of $435 million, driven by contributions from growth investments. The company reaffirmed its 2026 CAFD guidance and initiated 2027 guidance, while highlighting an accelerating growth roadmap with its sponsor-developed pipeline reaching approximately 16 GW.

Term
Q3 2026

“Since last quarter, we have committed to two additional drop-downs from Clearway Energy Group LLC (“Clearway Group”), secured further revenue contracting for our Flexible Generation fleet at long contract tenors, and increased our committed and identified drop-down opportunities (which have increased by over 100% since the beginning of the year), enabling us to reiterate a pathway to the top end or better of our 2030 CAFD per share target.”

Craig Cornelius, the Company’s President and Chief Executive Officer

“Following our annual strategic planning process, we are also pleased to announce our initial 2031 financial target range of $3.20 to $3.40 of CAFD per share, representing a compound annual growth rate of 7–8% from our 2025 baseline.”

Craig Cornelius, the Company’s President and Chief Executive Officer
4:12 PM ET 8-K
Financial Results Amplify Energy Corp. AMPY

Amplify Energy Financial Results

Amplify Energy reported Q3 2026 financial results featuring a 9% sequential increase in total production to 7.4 MBopd, driven by development activity at the Beta field. The company reported a net loss of $18.9 million primarily due to commodity derivative changes, while achieving Adjusted EBITDA of $10.8 million and securing enhanced royalty relief at Beta.

Term
Q3 2026

“Our third-quarter results demonstrate tangible progress in unlocking the value of Amplify’s asset base, with growing production across both assets and significantly lower costs at Bairoil. During the third quarter, strong performance from the recently drilled C29 and C16 wells, together with End of Life royalty relief, meaningfully increased net production, revenue and cash flow at Beta.”

Dan Furbee, the Company’s Chief Executive Officer
4:12 PM ET 8-K
Financial Results Network-1 Technologies, Inc. NTIP

Network-1 Technologies Financial Results

Network-1 Technologies reported a net loss of $2.33 million for Q3 2026 on zero revenue, compared to a $0.56 million loss in the prior year period. The increased loss was primarily driven by higher litigation-related professional fees and unrealized losses on marketable securities. The company continues to pursue patent litigation against Samsung with a trial date scheduled for June 2027.

Term
Q3 2026
4:12 PM ET 10-Q
Financial Results Insight Digital Partners II DYOR

Insight Digital Partners II Q3 2026 Results: Turns Profitable, Net Income $1.45M

Insight Digital Partners II reported net income of $1.45 million for the quarter ended September 30, 2026, primarily driven by $1.61 million in interest earned on investments held in the Trust Account. As a blank check company, it has not yet generated operating revenue and is currently focused on identifying a target for a business combination.

Key figure
Net income $1.45M
4:12 PM ET 10-Q
Financial Results Hyperfine, Inc. HYPR

Hyperfine Q3 2026 Results: Net Loss of $5.98M, Loss Narrows

Hyperfine, Inc. reported total sales of $13.77 million for the nine months ended September 30, 2026, a significant increase from $8.27 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $23.90 million for the period, though this was an improvement over the $29.66 million net loss reported in the same period of 2025.

Key figure
Net loss $5.98M
4:11 PM ET 10-Q
Financial Results Kaltura Inc KLTR ▶ Call

Kaltura Q3 2026 Results: Net Loss of $1.5M, Loss Narrows

Kaltura Inc. reported its financial results for the quarter ended September 30, 2026, maintaining its status as an accelerated filer and emerging growth company. The company continues to navigate a history of losses and geopolitical risks related to its operations in Israel, while focusing on the integration of AI technologies and subscription-based revenue growth.

Key figure
Net loss $1.5M
4:11 PM ET 10-Q
Financial Results Standard Premium Finance Holdings, Inc. SPFX

Standard Premium Finance Holdings Q3 2026 Results: Net Income $402K, Up 45.5% YoY

Standard Premium Finance Holdings reported total revenues of $10.36 million for the nine months ended September 30, 2026, a 12.3% increase over the prior year. Net income attributable to common stockholders rose to $1.10 million compared to $0.78 million in 2025, driven by higher finance charges despite increased interest expenses and credit loss provisions.

Key figure
Net income $402K · +45.5% YoY
4:11 PM ET 10-Q
Financial Results Independent Bank Corp INDB

Independent Bank Q3 2026 Results: Net Income $89.7M, Up 161.9% YoY

Independent Bank Corp reported net income of $89.7 million for the third quarter of 2026, a significant increase from $34.3 million in the prior year period, driven by higher net interest income and lower provisions for credit losses. Total assets remained stable at $25.0 billion, while the company experienced a decrease in total stockholders' equity due to share repurchases and accumulated other comprehensive losses.

Key figure
Net income $89.7M · +161.9% YoY
4:11 PM ET 8-K
Divestiture ZeroStack Corp. ZSTK

ZeroStack Divestiture to New Horizon Pharma B.V.

ZeroStack Corp. entered into a definitive agreement to sell 100% of its subsidiary, Phatebo GmbH, to New Horizon Pharma B.V. for an aggregate purchase price of €2,150,000. The closing of the transaction is subject to foreign direct investment clearance in Germany and other customary closing conditions.

Counterparty
New Horizon Pharma B.V.
4:11 PM ET 10-Q
Financial Results Uniti Group Inc. UNIT

Uniti Group Q3 2026 Results: Net Loss of $244M

For the nine months ended September 30, 2026, Uniti Group reported total revenues of $2.75 billion, a significant increase from $1.32 billion in the prior year period, though it recorded a net loss of $470.7 million compared to a net income of $1.61 billion in 2025. The company's balance sheet shows a total asset base of $13.5 billion and a shift to a total shareholders' deficit of $79.5 million as of September 30, 2026.

Key figure
Net loss $244M
4:11 PM ET 8-K
Financial Results Take Two Interactive Software Inc TTWO

Take Two Interactive Software Financial Results

Take-Two Interactive reported fiscal second quarter 2027 results with GAAP net revenue of $1.50 billion and a net loss of $54.0 million. The company reiterated its full-year Net Bookings guidance of $8.0 to $8.2 billion, driven by the upcoming launch of Grand Theft Auto VI.

Term
Q2 2027

“The launch of Grand Theft Auto VI is ten days away and, with pre-orders continuing to reach unprecedented levels, we expect to deliver an historic year for our company. We are reiterating our outlook for Fiscal 2027 Net Bookings of $8 to $8.2 billion, and are confident in our ability to build on this incredible year as we release new hits, explore emerging business opportunities, expand our geographic footprint, and pursue accretive M&A – all of which will set us on a path to unlock greater earnings power and long-term shareholder value.”

Strauss Zelnick, Chairman and CEO of Take-Two Interactive
4:11 PM ET 8-K
Financial Results GeneDx Holdings Corp. WGS

GeneDx Holdings Financial Results

GeneDx reported Q3 2026 revenue of $123.1 million, driven by 25% year-over-year growth in exome and genome test volume. The company achieved adjusted net income of $8.6 million and expanded its adjusted gross margin to 72%. Management reaffirmed full-year 2026 revenue guidance of $475 million to $490 million.

Term
Q3 2026

“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth. Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”

Katherine Stueland, CEO of GeneDx
4:11 PM ET 8-K
Financial Results Myomo, Inc. MYO

Myomo Financial Results

Myomo reported record third-quarter revenue of $12.3 million, a 22% year-over-year increase driven by a shift toward recurring patient sources. The company achieved breakeven Adjusted EBITDA and narrowed its full-year 2026 revenue guidance to the upper end of its previous range.

Term
Q3 2026

“The focus on our four success pillars helped deliver record revenue and solid operating leverage in the quarter, resulting in breakeven Adjusted EBITDA and sequentially lower cash burn.”

Paul R. Gudonis, Chairman and Chief Executive Officer
4:11 PM ET 10-Q
Financial Results Groupon, Inc. GRPN ▶ Call

Groupon Q3 2026 Results: Net Loss of $1.07M, Loss Narrows

Groupon, Inc. filed its 10-Q for the period ending September 30, 2026, highlighting a transition toward an AI-native business model and the implementation of a May 2026 restructuring plan. The company continues to manage significant debt obligations, including the 2026, 2027, and 2030 convertible senior notes, while navigating global economic uncertainty and inflationary pressures.

Key figure
Net loss $1.07M
4:11 PM ET 10-Q
Financial Results Immunome Inc. IMNM

Immunome Q3 2026 Results: Net Loss of $85.8M, Loss Widens

Immunome Inc. reported a net loss of $212.4 million for 2025, an improvement from $293.0 million in 2024, primarily due to a significant decrease in in-process research and development expenses. The company significantly strengthened its liquidity position, ending 2025 with $653.5 million in cash and cash equivalents following two major public offerings that raised over $594 million in net proceeds.

Key figure
Net loss $85.8M
4:11 PM ET 8-K
Loan & Debt Texas Instruments Inc TXN

Texas Instruments $2B Debt Financing with J.P. Morgan Securities LLC

Texas Instruments consummated the issuance and sale of $2 billion in senior notes across four tranches maturing in 2028, 2031, 2033, and 2036. The offering was conducted under an underwriting agreement with a syndicate led by J.P. Morgan, Citigroup, BofA Securities, and U.S. Bancorp. The notes carry interest rates ranging from 5.000% to 5.750%.

Value
$2B
Counterparty
J.P. Morgan Securities LLC, Citigroup Global Markets Inc., BofA Securities, Inc. and U.S. Bancorp Investments, Inc.
Term
through 2036
4:11 PM ET 8-K
Loan & Debt Nisource Inc. NI

Nisource $600M Debt Financing with BMO Capital Markets Corp.

NiSource Inc. completed the sale of $600 million in 5.400% Senior Notes due 2032. The company intends to use the net proceeds for general corporate purposes, including financing capital expenditures, working capital, and repaying existing indebtedness.

Value
$600M
Counterparty
BMO Capital Markets Corp., KeyBanc Capital Markets Inc., Mizuho Securities USA LLC and PNC Capital Markets LLC
Term
through 2032
4:11 PM ET 10-Q
Financial Results Bicara Therapeutics Inc. BCAX

Bicara Therapeutics Q3 2026 Results: Net Loss of $71.2M, Loss Widens

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing ficerafusp alfa, reporting 66,387,197 shares of common stock outstanding as of November 3, 2026. The company continues to incur significant financial losses and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key figure
Net loss $71.2M
4:11 PM ET 8-K
Financial Results Crescent Capital BDC, Inc. CCAP

Crescent Capital BDC Financial Results

Crescent Capital BDC reported Q3 2026 financial results with net investment income of $0.37 per share and a net asset value of $17.72 per share. The company also declared a $0.34 per share quarterly dividend and authorized a new $50 million share repurchase program.

4:11 PM ET Form 4
Insider Selling Nisource Inc. NI

Nisource EVP & CFO Shawn Anderson Sells $296K of Stock

Shawn Anderson, EVP & CFO, sold 6,500 shares of Nisource Inc. at $45.58 a share, worth $296K in total on Nov 5, 2026. Shares held after the trade: 153,580 (-4.1%).

Value
$296K
Shares
6,500
Price
$45.58
Role
EVP & CFO
Holding change
-4.1%
Trade date
Nov 5, 2026
4:11 PM ET 8-K
Financial Results Greystone Housing Impact Investors LP GHI

Greystone Housing Impact Investors Financial Results

Greystone Housing Impact Investors LP reported Q3 2026 net income of $3.2 million and Cash Available for Distribution (CAD) of $3.8 million. The Partnership is executing a strategic shift to reduce capital allocation in market-rate multifamily joint ventures in favor of tax-exempt mortgage revenue bond investments to stabilize long-term earnings.

Term
Q3 2026

“The Partnership continues to work with the managing members of our market rate multifamily properties to position our remaining investments in this segment for sale. We are working with third-party brokers and property management firms to plan potential exit timelines based on current property level leasing activity and operating results. We are also working with our internal origination team and the broader Greystone affordable platform to identify traditional mortgage revenue bond investment opportunities where we can redeploy capital.”

Kenneth C. Rogozinski, Chief Executive Officer of the Partnership

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.